Treatment for Kaposi sarcoma herpesvirus: Great challenges with promising accomplishments

Ravit Arav-Boger

doi:10.1007/s11262-008-0325-y

Treatment for Kaposi sarcoma herpesvirus: Great challenges with promising accomplishments

Ravit Arav-Boger

School of Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.

Original language	English (US)
Pages (from-to)	195-203
Number of pages	9
Journal	Virus Genes
Volume	38
Issue number	2
DOIs	https://doi.org/10.1007/s11262-008-0325-y
State	Published - Apr 2009

Keywords

Angiogenesis inhibitors
Antivirals
Chemotherpy
Ganciclovir
Highly active antiretroviral therapy
Kaposi sarcoma herpes virus
MTOR
Primary effusion lymphoma
Rapamycin
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Molecular Biology
Genetics
Virology

Access to Document

10.1007/s11262-008-0325-y

Cite this

@article{5ba7c61f912b4ae59f03ae9fa34b0165,

title = "Treatment for Kaposi sarcoma herpesvirus: Great challenges with promising accomplishments",

abstract = "Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.",

keywords = "Angiogenesis inhibitors, Antivirals, Chemotherpy, Ganciclovir, Highly active antiretroviral therapy, Kaposi sarcoma herpes virus, MTOR, Primary effusion lymphoma, Rapamycin, Tyrosine kinase inhibitors",

author = "Ravit Arav-Boger",

year = "2009",

month = apr,

doi = "10.1007/s11262-008-0325-y",

language = "English (US)",

volume = "38",

pages = "195--203",

journal = "Virus Genes",

issn = "0920-8569",

publisher = "Springer Netherlands",

number = "2",

}

TY - JOUR

T1 - Treatment for Kaposi sarcoma herpesvirus

T2 - Great challenges with promising accomplishments

AU - Arav-Boger, Ravit

PY - 2009/4

Y1 - 2009/4

N2 - Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.

AB - Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease. Treatment modalities for KSHV have largely been developed based on understanding its molecular pathogenesis. The KSHV genome has been fully sequenced and contains numerous genes with homology to human regulatory genes that are potentially important in KS development. Therapeutic strategies have been developed to target signaling pathways that are activated by KSHV. This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.

KW - Angiogenesis inhibitors

KW - Antivirals

KW - Chemotherpy

KW - Ganciclovir

KW - Highly active antiretroviral therapy

KW - Kaposi sarcoma herpes virus

KW - MTOR

KW - Primary effusion lymphoma

KW - Rapamycin

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=61849139074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849139074&partnerID=8YFLogxK

U2 - 10.1007/s11262-008-0325-y

DO - 10.1007/s11262-008-0325-y

M3 - Review article

C2 - 19139983

AN - SCOPUS:61849139074

SN - 0920-8569

VL - 38

SP - 195

EP - 203

JO - Virus Genes

JF - Virus Genes

IS - 2

ER -

Treatment for Kaposi sarcoma herpesvirus: Great challenges with promising accomplishments

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this